Pediatric Gastroparesis Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

147 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-23

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the Pediatric Gastroparesis Registry is to create a national prospective registry of children and adolescents with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ghrelin and Gastric Emptying in Children With Functional Dyspepsia

NCT01591174

Functional Dyspepsia

COMPLETED

Compassionate Use of Domperidone for Refractory Gastroparesis

NCT04699591

GERD Gastroesophageal Reflux Gastroparesis

RECRUITING NA

Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness

NCT03011151

Gastroparesis Gastrointestinal Disorder, Functional Critical Illness

UNKNOWN

Domperidone in Refractory Gastroparesis

NCT00760461

Gastroparesis

TERMINATED PHASE2

Mechanisms and Management of Infant Dysphagia

NCT02583360

Dysphagia Airway Aspiration Airway Penetration

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the Pediatric Gastroparesis Registry (PGpR), we will collect detailed epidemiological, clinical, psychological, and patient outcome data with the goal of classifying patients with gastroparesis and gastroparesis-like syndromes into pathophysiologically defined phenotypes.

The Primary Objective is to create a national prospective registry of children and adolescents with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying) to include:

1. Demographic, clinical, psychological, nutritional characteristics, physiological measures, and serial assessments of symptoms over 3 years while receiving clinical care;
2. Establish a Biorepository of plasma, serum, peripheral blood mononuclear cells (PBMC), GI mucosal biopsies (in those undergoing upper GI endoscopy), urine and stool collected from the children and adolescents in this registry which will allow for future analyses such as cytokines, bacterial DNA and microbiome to investigate the etiology and pathogenesis of gastroparesis in children.

Secondary Objectives:

1. To determine what factors, if any, play a role in the outcomes of children who do not improve within two years of diagnosis
2. To assess the spectrum of symptom severity of the cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness (and upper abdominal pain, if present) in children with gastroparesis
3. To assess several areas of gastric motility in pediatric patients with symptoms of gastroparesis (e.g., intragastric meal distribution, global gastric emptying)
4. To capture the clinical symptomatic course (outcome) of pediatric patients followed in the registry
5. To determine whether gastroparesis symptoms are correlated with gastric emptying in a pediatric population
6. To characterize abdominal pain in patients with gastroparesis and gastroparesis-like syndrome by using questionnaires, water load satiety testing and quantitative sensory testing (QST)
7. Determine the prevalence of hypermobility spectrum disorders in pediatric patients with gastroparesis
8. To determine if the volume of water consumed during the water load satiety test is an indirect measure of gastric accommodation
9. To determine if the water load satiety test is associated with an increased severity of gastroparesis symptoms (fullness, bloating, abdominal pain, etc).
10. To compare the intragastric meal distribution during scintigraphy to symptoms of early satiety, postprandial fullness in patients with symptoms of gastroparesis
11. Define immune cell profiles, cytokine induction and epigenetic changes in diabetic and idiopathic gastroparesis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroparesis Gastroparesis-like Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ages 5-9, gastroparesis

Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)

No interventions assigned to this group

Ages 5-9, gastroparesis-like syndrome

Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying

No interventions assigned to this group

Ages 10-17, gastroparesis

Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)

No interventions assigned to this group

Ages 10-17, gastroparesis-like syndrome

Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cardinal symptoms of gastroparesis of at least 12 weeks duration. Cardinal symptoms of gastroparesis are the constellation of some combination of: nausea, vomiting, early satiety, postprandial fullness; symptoms sometimes may be accompanied by upper abdominal pain
* An etiology of either diabetic, idiopathic, or post-fundoplication gastroparesis or gastroparesis-like disorder (symptoms of gastroparesis but normal gastric emptying; see below)
* Gastric emptying scintigraphy (GES) of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 12 months with either:

1. Abnormal gastric emptying rate defined as an abnormal 2-hour (\>60% retention) and/or 4-hour (\>10% retention) result based on a 4-hour scintigraphic gastric emptying study. (This group will comprise \~75% of patients in the registry)
2. Patients with a normal gastric emptying rate, but who have symptoms of gastroparesis. (This group will comprise \~25% of patients in the registry)
* Age at least 5 years, and under 18 years at initial screening visit

Exclusion Criteria

* Inability to comply with or complete the scintigraphic gastric emptying test (including allergy to eggs)
* Pregnancy
* Autism spectrum disorder, significant developmental delay, psychosis, or a history of bipolar disorder (because of inability to complete the gastroparesis symptom questionnaires: 24-hour recall and gastroparesis cardinal symptom questionnaire (the latter to be completed during the scintigraphy if possible)
* Use of narcotic analgesics greater than three days per week
* Presence of conditions associated with GI mucosal disease (e.g., inflammatory bowel disease, known eosinophilic gastroenteritis or eosinophilic esophagitis)
* Presence of any other condition that could cause delayed gastric emptying including:

1. Gastrointestinal obstruction confirmed by EGD, UGI, or abdominal CT
2. Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions
3. Acute or chronic renal failure (abnormal creatinine for age) and/or on hemodialysis or peritoneal dialysis
4. Acute liver failure
5. Advanced liver disease (features of portal hypertension)
* Clinically significant congenital heart disease (i.e., vagal injury during cardiac repair)
* History of esophageal, gastric or bowel surgery excepting prior fundoplication
* Metabolic disease including mitochondrial disease and inborn errors of metabolism
* Chronic lung disease (including cystic fibrosis)
* A serious chronic medical condition (e.g., cystic fibrosis)
* Use of medications that can affect motility during the gastric emptying study
* Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements
* Inability to obtain informed consent/assent

Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No